| 前收市價 | 27.50 |
| 開市 | 27.62 |
| 買盤 | 26.90 x 200 |
| 賣出價 | 26.96 x 200 |
| 今日波幅 | 26.68 - 27.18 |
| 52 週波幅 | 24.53 - 38.80 |
| 成交量 | |
| 平均成交量 | 602,359 |
| 市值 | 17.102B |
| Beta 值 (5 年，每月) | 0.86 |
| 市盈率 (最近 12 個月) | 21.54 |
| 每股盈利 (最近 12 個月) | 1.25 |
| 業績公佈日 | 2024年11月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 39.40 |
Insider MonkeyGenmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
We recently compiled a list of the 10 Best Affordable Stocks Under $40 According to Short Sellers. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other affordable stocks under $40. Several traders tend to profit from stocks through appreciation. However, some do the opposite– their idea […]
ZacksAbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
ZacksWall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
